AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Capricor Plunges 10.03% Amid Fraud Lawsuits
Generated by AI AgentAinvest Pre-Market Radar
Monday, Aug 11, 2025 9:34 am ET1min read
Aime SummaryOn August 11, 2025, Capricor's stock experienced a significant drop of 10.03% in pre-market trading, reflecting a notable decline in investor sentiment.
Capricor Therapeutics, Inc. is currently facing multiple securities fraud lawsuits, which have contributed to the recent decline in its stock price. The Schall Law Firm, along with other legal entities, has filed class action lawsuits against the company, alleging violations of the Securities Exchange Act of 1934. These lawsuits claim that
made false and misleading statements regarding its deramiocel drug candidate, particularly concerning its progress towards FDA approval and the concealment of adverse data from the Phase 2 HOPE-2 trial.Investors who purchased Capricor's securities between October 9, 2024, and July 10, 2025, are encouraged to participate in these lawsuits to recover their losses. The legal actions highlight the potential risks associated with investing in biotech companies, especially those with ongoing clinical trials and regulatory approval processes. The outcome of these lawsuits could have a significant impact on Capricor's future operations and investor confidence.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Society Pass surges 16.92% following $3 million stock offering priced at $2.00 per share
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership expansion with European biotech entity.
Jan.02 2026
Olaplex plunges 7.59% as broader market pressures drive investor sentiment reversal
Jan.02 2026
Real Brokerage Inc. (REAX) Surges 7.04% on Renewed Investor Confidence in Long-Term Strategic Positioning
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership expansion and FDA Breakthrough Therapy Designation.
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet